Bayesian adaptive trial design for a newly validated surrogate endpoint

DOI10.1111/J.1541-0420.2011.01647.XMaRDI QIDQ2894012zbMATH OpenOpenAlexWikidataFDO

Authors Lindsay A. Renfro, Daniel J. Sargent, Bradley P. Carlin

Publication date 27 June 2012

Published in Biometrics (Search for Journal in Brave)

Full work available at URL http://europepmc.org/articles/pmc3218207

zbMATH Keywords

clinical trialssurvival analysis

Mathematics Subject Classification ID

Bayesian inference (62F15) Applications of statistics to biology and medical sciences; meta analysis (62P10) Medical applications (general) (92C50)

Recommendations

• Validation of Surrogate end Points in Multiple Randomized Clinical Trials with Failure Time end Points
• The evaluation of surrogate endpoints.
• The meta-analytic framework for the evaluation of surrogate endpoints in clinical trials
• The validation of surrogate endpoints in meta-analyses of randomized experiments
• Criteria for the Validation of Surrogate Endpoints in Randomized Experiments

Cites work

• Bayesian adaptive methods for clinical trials
• scientific article; zbMATH DE number 3385132 (Why is no real title available?)
• Validation of Surrogate end Points in Multiple Randomized Clinical Trials with Failure Time end Points

Cited in

(2)

• scientific article; zbMATH DE number 5898591 (Why is no real title available?)
• A combined proof of concept and dose finding study with multiple endpoints: A Bayesian adaptive design in chronic prostatitis/chronic pelvic pain syndrome

This page was built for publication: Bayesian adaptive trial design for a newly validated surrogate endpoint

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q2894012)